Samarpan Majumder,  Ph.D.

Assistant Professor of Genetics


Stanley S Scott Cancer Center

1700 Tulane Avenue, Rm# 906

New Orleans, LA 70112

Ph# 504-210-2670



Ph.D (Biochemistry) Calcutta University, Calcutta, India (awarded 2000)


Dr. Majumder joined the Department of Genetics at LSUHSC in November 2017 after spending 20 years in acdemia and biotech industries. Dr. Majumder received his postdoctoral training in the University of North Carolina (UNC) at Chapel Hill.and worked in the field of Drosophila genetics. He was Instrumental in finding a novel gene (mei9) in fruit fly, drosophila, that is involved in nucleotide excision repair (NER). In 2003, he joined at Lineberger Comprehensive Research Center in UNC, Chapel Hill and worked in prostate cancer research. While working in this field, he 1. Documented the importance of breast cancer gene, her2, in the late stage of prostate cancer progression. 2. Identified the involvement of Coactivator Associated Arginine Methyltransferase (CARM1) and the importance of epigenetics in prostate cancer progression and 3. contributed to implicate Ack1, a growth promoting cellular protein, in late stage of prostate cancer. From 2006 to 2009, he worked with Prof. Bryan Roth at Dept. of Pharmacology in UNC and was actively involved in National Institute of Mental Health's (NIMH) psychoactive drug discovery program. He Collaborated with University of Wisconsin at Milwaukee and screened compounds that resulted in some peer reviewed publications (5) and compounds with high therapeutic potentials.

 In 2009, Dr. Majumder accepted an offer from an early stage biopharmaceutical company, Vascular Pharmaceutical, NC,and, joined there as Director-Preclinical Development. In this capacity, he was responsible in guiding A) Vascular's day to day research activities comprising of a team of researchers (3) in their effort to design, develop and commercialize a novel antibody against diabetes accelerated heart complications and B) Successfully coordinated preclinical studies in pigs to validate the efficacy of in-house monoclonal antibody.

From 2012 to 2016, Dr. Majumder worked as a Sr. Scientist in another biotech company, Novametics, NC, and led company's effort to develop and commercialize a novel dignostic assay kit to detect blood clotting disorders. Dr. Majumder successfully A) validated and optimized a novel diagnostic clotting assay with a patented component to detect blood coagulation disorders. B) Collaborated with senior management and cross-functional stakeholders to enable selection of appropriate assay platform and formulation of kits. C) Manage a team of cross functional scientists (up to 5) from various disciplines to ensure that all timelines and project deliverables were met. He was in charge of Novametics scientific execution and played an important role in company's strategy and business development. D) Worked with subject matter expert (SME) to facilitate the clinical trial of patient samples at Duke and UNC.and E) Positioned the company into a "sweetspot"  for a licensing agreement with big healthcare companies.

Research Interests

Dr. Majumder has been recruited in this department to bolster department's strong focus on cancer research, and specifically, breast cancer research program. He brings with him his valuable experience in industry and his previous translational research experience in cancer to integrate and navigate a few ongoing breast cancer research projects. As an investigator, his main focus is on estrogen receptor positive (ER+) endocrine therapy resistant breast cancer (BC). He has been collaborating with a swiss phramaceutical company, Cellestia Biotech (https://www.cellestia.com/) and has successfully led Cellestia's lead compound, CB-103 to test the safety and efficacy of CB-103 in the preclinal model of ER+ endocrine therapy resistant breast cancer. His other active research of interest is to gain insight into the role of gut microbiome in triple-negative breast cancer (TNBC); specially in obese african-american (AA) women. He is an expert in the field of preclinical model of cancer, cancer immunotherapy, tumor microenvironment, cancer stem cells and exosomes. He writes his own grant and actively seeking funding from NIH and DOD. In addition, he also cooperates, collaborates, writes and submits grants with Dept. chair,  Prof. Lucio Miele. Dr,. Majumder also serves in various departmental and institutional committees and takes avid interest in teaching. Dr. Majumder also serves in the editorial board of a few international journals. Dr. Majumder likes to travel and lives with his wife in New Orleans. 

Teaching Activities


Course Number: GENET245/BIOCH260

Course Title: Cancer Molecular genetics and application

Course Directors:  Samarpan Majumder, Ph.D. and suresh Alahari, Phh. D.

Course Description: Graduate students who want to pursue cancer research in future should consider to take this course. This upper level course offers students to gain insight into the types of genetic alterations and beyond genes (epigenetics) that contribute to cancer development and progression. In addition, the course posits some of the recent therapies and genomics tools that revolutionized the field of clinical onocolgy to the students. By the end of the course, students should have a comprehensive understanding of the driver mutations that causes cancer, the role of epigenetics in cancer, recent progress in the cancer diagnosis, treatment, precision medicine etc. We assembled a formidable team of instructors who are experts in their own fields in this course.Course

Credits: 3

Course Number: GENET 299 

Course Title: Seminar in Human Genetics

Course Directors: Fokhrul Hossain, Ph.D. and Samarpan Majumder, Ph.D.

Course Description: Reports on research progress and on current literature. A total of four credits must be earned during the period of graduate work.

Course Credits: 1

Critical Skill Integration (CSI) course for Medical School:

I participate in ~15 hrs/yr of teaching in this course.


Committees & Administrative Responsibilities

LSUHSC Committee

Committee on International Travel

August 2020- Present

Selected Publications

Selected Publications in the last two years:

  1. Hossain F, Majumder S*, David J, Bunnell BA, Miele L. Obesity modulates gut microbiome in Triple-negative breast cancer (TNBC). Nutrients. 2021 Oct 19;13(10):3656. doi: 10.3390/nu13103656.(*Co-first author). PMID: 34684657 
  2. Hossain F, Majumder S, David J and Miele L. Precision Medicine and Triple-Negative Breast Cancer: Current Landscape and Future Directions Cancers (Basel) 2021 Jul 26; 13(15):3739. PMID: 34359640
  3. Majumder S, Crabtree JS, Golde TE, Minter LM, Osborne BA, Miele L. Targeting Notch in oncology: the path forward. Nat Rev Drug Discov.  2021 Feb; 20 (2):125-144. PMID: 33293690
  4. Sengupta T, Majumder R, Majumder S*. Role of vitamin D in treating COVID-19-associated coagulopathy: problems and perspectives. Mol Cell Biochem 2021 Feb 18; 1-7 (*Co- Corresponding author). PMID: 33604809
  5. Chatterjee S, Sengupta T, Majumder S*, Majumder R COVID-19: a probable role of the anticoagulant Protein S in managing COVID-19-associated coagulopathy. Aging (Albany NY) 2020 Aug 19; 12(16):15954-15961. (*Co-corresponding author). PMID: 32826388

 Full Publications: